NCT01874626已完成3 期
A Randomized, Double-blind, Placebo-controlled, Multi-dose, Pivotal Study to Determine the Efficacy and Safety of SST 0225, a Topical Ibuprofen Cream, in the Treatment of Pain Associated With Acute Ankle Sprain.
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 305
- 试验地点
- 1
- 主要终点
- 24 Hour SPID
研究概览
简要总结
This is a randomized, multi-center, double-blind, placebo-controlled, multi-dose, parallel-group study. Approximately 300 subjects (150 per group) 16 years of age and older with a current (within 24 hours from Visit 1) Grade I or II ankle sprain, and who meet all eligibility criteria, will be randomized into the study and will receive either the active treatment (SST-0225 ibuprofen cream), or matching placebo. Subjects will apply an amount equivalent to a 4 inch line of investigational product to the affected ankle approximately every 4-6 hours. At Visit 1 two doses will be applied at the site. All subsequent doses of the investigational product will be applied every 4 to 6 hours with a total of 4 doses in a 24 hour period. Duration of treatment with the investigational product is 7 days.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Triple (Participant, Care Provider, Investigator)
入排标准
- 年龄范围
- 16 Years 至 —（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male and female subjects ≥16 years of age
- •Grade I or II acute ankle sprain injury within 24 hours prior to first use of investigational product.
- •Grade I: when the ligament is stretched but not torn and the anterior talofibular ligament is usually involved. The anterior drawer test is negative
- •Grade II: moderate sprain, which usually results in partial tears of the ligaments, primarily the anterior talofibular and possibly the calcaneofibular ligament. Ligamentous laxity may be present and there is moderate swelling
- •At screening (Visit 1), subject reported pain intensity score upon movement of ≥ 5 on a 0-10 Numerical Rating Scale (NRS)
- •Subject's Assessment of Normal Function/Activity (must be > 2) at screening
- •Able to comply with the visit schedule
- •Able to apply the investigational product as directed
- •Females of childbearing potential must be willing to use an approved method of birth control during study participation. Subjects currently using any of the below mentioned contraception methods, must have used the method for a minimum of three months prior to study enrollment, and must be willing to continue its use (at the same dose) throughout the study.
- •Effective methods of birth control: e.g. prescription oral, vaginal or transdermal contraceptives; contraceptive implants or injections; intrauterine device; diaphragm/cervical cap/condom with spermicide
- •Other acceptable methods of birth control include: Postmenopausal or amenorrhea for one year, Surgically sterile (hysterectomy, tubal ligation, or oopherectomy), Premenarcheal
- •Able to speak, read and comprehend English and record requested measurements as outlined in the protocol
- •Subject must be able to read, understand, sign and date the informed consent document (and the subject assent form, if necessary) indicating that the subject (or a legally acceptable representative) has been informed of all pertinent aspects of the trial
排除标准
- •Subjects meeting any of the following criteria will not be entered in the study:
- •Similar injury of the same joint within the last 6 months
- •Clinical evidence of complete rupture of ankle ligaments (third degree sprain)
- •Requirements for bed rest, hospitalization, or surgical intervention for the ankle injury
- •Evidence of fractures or non-removable full cast of any type
- •Presence of bilateral occurrence of ankle injury or ipsilateral ankle and/or knee injury
- •Open wound or infection at site of injury
- •Significant Skin irritation at the application site;
- •Use of longer half life NSAID within 12 hours prior to study entry (Appendix 4)
- •Does not agree to use only supplied investigational product and rescue medication for analgesia during the seven days of the study or expects to require analgesics during the study for pain other than for ankle pain
- •Presence or history of allergy or intolerance to aspirin, NSAIDs, acetaminophen or any of the excipients in the investigational product (L-Arginine hydrochloride, Glyceryl Stearate, Cetyl Alcohol, Squalane, Xanthan Gum, Isopropyl Myristate, Oleic Acid, Propylene Glycol, Polysorbate -20)
- •Medical conditions including: peptic ulcer disease; clinically important gastrointestinal, renal, or hepatic disease within the past 6 months; clinically significant cardiovascular disease not stable for the past 6 months; uncontrolled hypertension as indicated by systolic blood pressure greater than or equal to 160 mmHg or a diastolic blood pressure greater than or equal to 100 mm Hg; coagulation disorders or hematologic disease; history of seizures; or known, significant, pre-existing conditions that would affect the interpretation of any potential adverse reactions to the study medication
- •Known alcohol abuse, drug dependency, or history of significant psychiatric illness within the past 12 months
- •Females who are pregnant or lactating.
研究组 & 干预措施
Active
Active Comparator
SST-0225 Topical Ibuprofen Cream (investigational product) Dose: 2.7 grams of cream containing 200 mg ibuprofen
干预措施: SST-0225 Topical Ibuprofen Cream (Drug)
Placebo
Placebo Comparator
Placebo topical formulation (Reference product)
干预措施: Placebo (Drug)
结局指标
主要结局
24 Hour SPID
时间窗: 24 Hours
Tme weighted summed pain intensity on movement difference from baseline over the first 24 hours (SPID24) following the first application of study medication on Day 1
次要结局
- Use of rescue medication including time to first use(7 days)
- Mean change from baseline in pain scores on movement(First 24 hours)
- Subject's global evaluation of investigational product(7 days)
- Change from baseline in pain scores on movement(7 days)
- Time to onset of confirmed perceptible pain relief and onset of meaningful pain relief(First 4 hours)
- Number and percent of patients with systemic and local (skin) self-reported adverse events(7 days)
- Mean change from baseline in subject reported pain intensity(First 4 hours)
- Percent of subjects with > 15%, > 30% and > 50% reductions in pain intensity(First 24 hours)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Safety Study of AMG 557 in Subjects With Lupus ArthritisLupus Arthritis, Systemic Lupus ErythematosusNCT01683695Amgen20
已完成
2 期
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Bayesian Adaptive Randomization Design, Dose Response Study of the Efficacy of E2006 in Adults and Elderly Subjects With Chronic InsomniaChronic InsomniaAdultsElderlyNCT01995838Eisai Inc.291
已完成
1 期
ALK33BUP-201: Safety and Tolerability Study of ALKS 33-BUP (ALKS 5461) Administration in Subjects With MDDMajor Depressive DisorderNCT01381107Alkermes, Inc.32
已完成
2 期
Study on OMT-28 in Maintenance of Sinus Rhythm in Patients With Persistent Atrial Fibrillation (AF)Atrial FibrillationNCT03906799Omeicos Therapeutics GmbH136
已完成
2 期
Lenrispodun as Adjunctive Therapy in the Treatment of Patients With Motor Fluctuations Due to Parkinson's DiseaseParkinson DiseaseNCT05766813Intra-Cellular Therapies, Inc.79